궤양성 대장염에서 관해 유도와 관해 유지를 위한 약물 용량, Medical therapy of active ulcerative colitis

Medical therapy of active ulcerative colitis

Role	Medication	Trade name (United States or as noted)	Daily dose
Induction of remission	Topical (rectal) mesalamine*
	Suppository	Canasa	1 gram (one suppository) once or twice daily
	Retention enema	Rowasa	4 grams (one 60 mL unit) once or twice daily
	Topical (rectal) glucocorticoids
	Hydrocortisone suppository	Proctocort, Hemril	One suppository (25 or 30 mg) once or twice daily
	Hydrocortisone aerosol foam 10 percent	Cortifoam	90 mg (one applicatorful) once or twice daily
	Hydrocortisone enema	Cortenema, Colocort	100 mg (one 60 mL unit) once or twice daily
	Oral 5-aminosalycylic acid (5-ASA) derivatives
	Sulfasalazine	Azulfidine, Salazopyrin¶	4 grams per day in four divided doses
	Mesalamine*
	Delayed release enteric coated tablet	Asacol¶, Asacol HD	2.4 to 4.8 grams daily in three divided doses
	Capsule containing delayed release enteric coated tablet	Delzicol	2.4 to 4.8 grams daily in three divided doses
	Delayed and extended release tablet, multimatrix (MMX)	Lialda, Mezavant¶	2.4 to 4.8 grams daily once daily
	Capsule containing delayed release enteric coated granules	Apriso	1.5 to 4.5 grams once each morning
	Controlled release capsule	Pentasa	2 to 4 grams daily in four divided doses
	Mesalamine pellets	Salofalk¶	1.5 to 4 grams daily in one to three divided doses
		Pentasa sachet¶	2 to 4 grams daily in two to four divided doses
	Olsalazine capsule	Dipentum	2 to 3 grams daily in two to four divided doses
	Balsalazide capsule	Colazal	2.25 to 6.75 grams daily in three divided doses
	Balsalazide tablet	Giazo	2.2 to 6.6 grams daily in two divided doses
	Glucocorticoids
	Budesonide delayed and extended release tablet, multimatrix (MMX)	Uceris	9 mg once each morning for eight weeks
	Prednisone or oral prednisolone		40 to 60 mg once each morning or in two divided doses
	Intravenous prednisolone¶		30 mg IV every 12 hours
	Methylprednisolone	Solu-Medrol	16 to 20 mg IV every eight hours
	Hydrocortisone	Solu-Cortef	100 mg IV every eight hours
Maintenance of remission	Topical (rectal) mesalamine*
	Suppository	Canasa	1 gram (1 suppository) at bedtime
	Enema	Rowasa	2 to 4 grams (30 to 60 mL) at bedtime
	Oral 5-aminosalycylic acid (5-ASA) derivatives
	Sulfasalazine	Azulfidine, Salazopyrin¶	4 grams daily in three or four divided doses
	Mesalamine*
	Delayed release enteric coated tablet	Asacol¶, Asacol HD	1.6 to 2.4 grams daily in one to three divided doses (depending upon preparation)
	Capsule containing delayed release enteric coated tablet	Delzicol	1.6 to 2.4 grams daily in one to three divided doses
	Delayed and extended release tablet, multimatrix	Lialda, Mezavant¶	2.4 to 3.6 grams once daily
	Capsule containing delayed release enteric coated granules	Apriso	1.5 to 3 grams once each morning
	Controlled release capsule	Pentasa	1.5 to 4 grams daily in four divided doses
	Mesalamine pellets	Salofalk¶	0.75 to 4 grams daily in one to three divided doses
		Pentasa sachet¶	1.5 to 4 grams once daily
	Olsalazine capsule	Dipentum	1 gram daily in two divided doses
	Balsalazide capsule	Colazal	2.25 to 6.75 grams daily in three divided doses
	Balsalazide tablet	Giazo	2.2 to 6.6 grams daily in two divided doses

Sulfasalazine and mesalamine (Delzicol, Asacol, Pentasa, and Lialda) are approved by the US Food and Drug Administration (FDA) for treatment and maintenance of remission of active ulcerative colitis; mesalamine (Asacol HD) and balsalazide (Colazal, Giazo) are approved for treatment of active ulcerative colitis (approval of Giazo is limited to male patients), while olsalazine (Dipentum) is approved for maintenance therapy in patients who are allergic to sulfasalazine. Encapsulated mesalamine granules (Apriso) is approved for maintenance of remission by the US FDA.

5-ASA: 5-aminosalicylate; IV: intravenous; US: United States.
* Mesalamine is US generic name. Mesalazine is an international generic (nonproprietary) name.
¶ Not available in US. Trade names shown are for products commonly available in areas other than US including Canada, United Kingdom, and Europe.

Data courtesy of authors with additional data from: Ordás I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet 2012; 380:1606.